Program
Access to the virtual sessions (lectures and short presentations) will require registration.
If you have registered before noon on October 1, 2021, you should have received instructions to access the virtual hub of our conference (check your spam folders, as well!).
You can access the virtual hub of the conference with the email address used to register for the event. If you have accessed our meetings of last year, you should connect with the password you set at that time. If, however, you do not remember that password or are logging in for the first time, simply click on “Forgot password” and then look for an email from us with instructions (once more, please check your spam box).
PROGRAM AT-A-GLANCE
Monday, October 4, 2021 – all times in US Eastern Time
Session/Lecture
10:00 ET
10:10
10:40
10:40
10:45
11:00
11:15
11:30
11:45
11:55
12:30
12:30
12:40
13:00
13:30
13:30
13:35
13:50
14:05
14:20
14:35
14:45
15:00
15:00
15:05
15:20
15:35
15:50
16:00
Chair/Speaker
10:00 ET
10:10
10:40
10:40
10:45
11:00
11:15
11:30
11:45
11:55
12:30
12:30
12:40
13:00
13:30
13:30
13:35
13:50
14:05
14:20
14:35
14:45
15:00
15:00
15:05
15:20
15:35
15:50
16:00
Tuesday, October 5, 2021 – all times in US Eastern Time
Session/Lecture
10:00 ET
10:30
10:30
10:35
10:50
11:05
11:20
11:30
11:30
11:50
12:15
12:15
12:20
12:35
12:50
13:05
13:15
The lack of representation of underserved and underrepresented communities in brain health research is an urgent issue for researchers, policymakers, health providers and patient advocates. Despite a higher risk for Alzheimer’s and related dementias, Black and Latino Americans are woefully underrepresented in federally and industry funded research, limiting the generalizability of research findings and limiting access to cutting-edge research. This session will highlight the health equity challenges behind the status quo and review concrete strategies for driving research equity in neuroscience research.
13:45
14:00
16:00
Chair/Speaker
10:00 ET
10:30
10:30
10:35
10:50
11:05
11:20
11:30
11:30
11:50
12:15
12:15
12:20
12:35
12:50
13:05
13:15
Jason Resendez, UsAgainstAlzheimer’s Center for Brain Health Equity
Panelists:
Gladys Maestre, MD, PhD, Rio Grande Valley Alzheimer’s Disease Resource Center for Minority Aging Research (AD-RCMAR), University of Texas Rio Grande Valley (UTRGV)
Stephanie Monroe, USAgainstAlzheimer's
13:45
14:00
16:00
REGISTRATION IS FREE!
PROGRAM DETAILS
CONFERENCE INTRODUCTION
Monday, October 4, 2021
10:00 US Eastern Time

Howard Fillit
Alzheimer’s Drug Discovery Foundation
Dr. Howard Fillit is ADDF’s Founding Executive Director and Chief Science Officer. His introduction will provide a welcome to our 22nd International Conference on Alzheimer’s Drug Discovery, a brief update on ADDF’s recent progress and will highlight the framework for this year’s meeting.
KEYNOTES



Jeffrey Cummings
UNLV
Kevin Yarasheski
C2N Diagnostics
Mark Mintun
Eli Lilly & Co., Inc.
Recommendations for Exploratory Trials in Dementia
Clinical Validation for Plasma AB42/AB40 as a Biomarker for Alzheimer’s Disease Pathology
The Evolving Role of Biomarkers in Clinical Trials
Monday, October 4, 2021
10:10 US Eastern Time
Monday, October 4, 2021
13:00 US Eastern Time
Tuesday, October 5, 2021
10:00 US Eastern Time
SESSIONS
SESSION I: CLINICAL TRIALS AND NOVEL APPROACHES FOR DEMENTIA





Alessio Travaglia
ADDF
CHAIR
Session Overview
Dirk Beher
Asceneuron
Frank Longo
PharmaTrophiX
Development of BDNF Receptor Modulators Targeting Amyloid- and Tau-related Degenerative Mechanisms
Ottavio Arancio
Neurokine
Phase 1 Studies and Preparation of Clinical Phase 2 IND of MW150: Novel Stress Kinase Inhibitor Candidate
Georg Terstappen
Cambrian Biopharma
Strategies for Delivering Therapeutics across the Blood Brain Barrier
Monday, October 4, 2021
10:40 US Eastern Time
Monday, October 4, 2021
10:45 US Eastern Time
Monday, October 4, 2021
11:00 US Eastern Time
Monday, October 4, 2021
11:15 US Eastern Time
Monday, October 4, 2021
11:30 US Eastern Time
PANEL DISCUSSION – SESSION I
Monday, October 4, 2021
11:45 – 11:55 US Eastern Time
POSTER SESSION/BREAK
This session will feature research from early investigators in the academic community focused on drug development for Alzheimer’s and related dementias.
Monday, October 4, 2021
11:55 – 12:30 US Eastern Time
START-UP FORUM
This session will feature drug development programs being pursued by start-up companies.

Tracy Saxton
Dolby Family Ventures
CHAIR
Investing in Dementia: Trends and Forward Outlook
Monday, October 4, 2021
12:30 – 13:00 US Eastern Time
SESSION II: ADVANCES IN FLUID BIOMARKERS





Shobha Purushothama
ADDF
CHAIR
Session Overview
Kaj Blennow
Univ. of Gothenburg
Russell Lebovitz
Amprion
Benfotiamine in Alzheimer’s Disease: A Pilot Study
Qinwen Mao
University of Utah
Plasma Pathologic TDP-43 as a Biomarker for FTLD-TDP
Thomas Montine
Stanford University
Blood-based Immune Biomarkers for Alzheimer’s Disease Diagnosis and Its Early Detection
Monday, October 4, 2021
13:30 US Eastern Time
Monday, October 4, 2021
13:35 US Eastern Time
Monday, October 4, 2021
13:50 US Eastern Time
Monday, October 4, 2021
14:05 US Eastern Time
Monday, October 4, 2021
14:20 US Eastern Time
PANEL DISCUSSION – SESSION II
Monday, October 4, 2021
14:20 – 14:30 US Eastern Time
POSTER SESSION/BREAK
Monday, October 4, 2021
14:45 – 15:00 US Eastern Time
SESSION III: DRUG DEVELOPMENT APPROACHES FOR FRONTOTEMPORAL DEMENTIA




Penny Dacks
AFTD
CHAIR
Session Overview
Giacomo Koch
Santa Lucia Foundation
Wen-Hsuan Chang
Acurastem
Kent Werner
Cogentis Therapeutics
Monday, October 4, 2021
15:00 US Eastern Time
Monday, October 4, 2021
15:20 US Eastern Time
Monday, October 4, 2021
15:35 US Eastern Time
PANEL DISCUSSION – SESSION III
Monday, October 4, 2021
15:50 – 16:00 US Eastern Time
SESSION IV: CLINICAL TRIALS 2–REPURPOSING APPROACHES FOR ALZHEIMER’S DISEASE




Jonathan Sabbagh
ADDF
CHAIR
Session Overview
Ihab Hajjar
Emory University
Novel Positive Allosteric Modulators of the Alpha1A-Adrenergic Receptor to Treat Alzheimer’s Disease
Miia Kivipelto
Karolinska Institute
Repurposing Metformin for Prevention of Alzheimer’s Disease
Miranda Orr
Wake Forest University
Phase 2 Clinical Trial to Evaluate the Safety and Feasibility of Senolytic Therapy in Alzheimer’s Disease
Tuesday, October 5, 2021
10:30 US Eastern Time
Tuesday, October 5, 2021
10:35 US Eastern Time
Tuesday, October 5, 2021
10:50 US Eastern Time
Tuesday, October 5, 2021
11:05 US Eastern Time
PANEL DISCUSSION – SESSION IV
Tuesday, October 5, 2021
11:20 – 11:30 US Eastern Time
START-UP FORUM
Tuesday, October 5, 2021
11:30 – 11:50 US Eastern Time
POSTER SESSION/BREAK
Tuesday, October 5, 2021
11:50 – 12:15 US Eastern Time
SESSION V: DIGITAL BIOMARKERS FOR DEMENTIA




Kristina Malzbender
Gates Ventures
CHAIR
Session Overview
Christy Sheehy
C. Light Technologies, Inc
Fixational Eye Motion as a Biomarker for Mild Cognitive Impairment
Lampros Kourtis
Circadic
Speech and Language as a Biomarker for Alzheimer’s
Rhoda Au
Boston University
Disease Digital Biomarker Discovery: From Concept to Research ImplementationSpeech and Language as a Biomarker for Alzheimer’s
Tuesday, October 4, 2021
12:15 US Eastern Time
Tuesday, October 4, 2021
12:20 US Eastern Time
Tuesday, October 5, 2021
12:35 US Eastern Time
Tuesday, October 4, 2021
12:50 US Eastern Time
PANEL DISCUSSION – SESSION V
Tuesday, October 5, 2021
13:05 – 13:15 US Eastern Time
SPECIAL SESSION: BUILDING EQUITY IN ALZHEIMER’S RESEARCH
Tuesday, October 5, 2021
13:15 – 13:45 US Eastern Time



Jason Resendez
USAgainstAlzheimer’s
MODERATOR
Gladys Maestre
UTRGV
Stephanie Monroe
USAgainstAlzheimer’s
CONCLUSIONS
Tuesday, October 5, 2021
13:45 – 14:00 US Eastern Time
NETWORKING/POSTERS
Tuesday, October 6, 2020
14:00 – 16:00 US Eastern Time